Bajaj Finance delivered a strong Q4 performance with profits reaching ₹54.64 billion. While Net Interest Margins (NIM) face slight pressure, improvements in Net Total Income (NTI) through OPEX optimization and a decline in credit costs to 145-160 BPS provide a stable growth outlook toward FY27 targets.
Market snapshot: Bajaj Finance continues to demonstrate superior execution in the NBFC space, reporting a 22% year-on-year increase in consolidated net profit. Despite anticipated margin compression, the lender's focus on operational efficiency and credit cost management underscores a robust medium-term profitability roadmap.
Summary: Bajaj Finance delivered a strong Q4 performance with profits reaching ₹54.64 billion. While Net Interest Margins (NIM) face slight pressure, improvements in Net Total Income (NTI) through OPEX optimization and a decline in credit costs to 145-160 BPS provide a stable growth outlook toward FY27 targets.
Bajaj Finance is successfully pivoting from a pure high-margin growth story to a high-efficiency institutional lender. The proactive guidance on NIM compression shows transparency, while the 25-40 BPS gain from OPEX optimization proves that the company is leveraging its massive technology stack to protect profitability. This execution is a primary differentiator in a tightening liquidity environment.
The positive earnings surprise and clear FY27 roadmap are likely to support valuation multiples for large-cap NBFCs. It signals that well-capitalized lenders can withstand margin pressures through operating leverage. We may see capital allocation shifts toward diversified NBFCs with strong credit cost controls.
Market Bias: Bullish
Strong 22% profit growth and a 25-40 BPS improvement in NTI offset NIM concerns. The lowering of credit costs to 145-160 BPS suggests superior asset quality.
Overweight: Diversified NBFCs, Consumer Finance, Banking
Underweight: Microfinance (MSME), Unsecured Small Ticket Lending
Trigger Factors:
Time Horizon: Medium-term (3-12 months)
The Indian NBFC sector is currently navigating a period of 'stabilized growth' following the RBI's tightening of risk weights on unsecured loans. Bajaj Finance’s ability to maintain stable asset quality (GNPA/NNPA) while targeting a 4.6% ROA places it in the top quartile of global financial services firms in terms of capital efficiency.
Bajaj Finance recently received the green light from the RBI to resume issuing loans under its 'eCom' and 'Insta EMI Card' products after a brief regulatory pause. This restoration of full digital lending capabilities was a key driver for the strong Q4 revenue growth of ₹191.7 billion.
As Bajaj Finance marches toward its FY27 goals of 4.6% ROA, it transitions from a growth-at-any-cost model to an efficiency-led powerhouse. For investors, the focus shifts from raw AUM growth to the consistency of credit costs and the management of Net Total Income.
The profit increase to ₹54.64 billion was driven by a 17.2% rise in revenue and significant improvements in operational efficiency, specifically a 25-40 BPS gain in Net Total Income through OPEX optimization.
While NIM compression usually concerns lenders, Bajaj Finance plans to offset this through lower credit costs (145-160 BPS) and better operating leverage. This balanced approach aims to maintain an ROA between 4.4% and 4.6%.
Yes, management has indicated that Gross Non-Performing Assets (GNPA) and Net Non-Performing Assets (NNPA) are expected to stay stable, supported by a drop in credit costs to the 145-160 BPS range.
High Performance Trading with SAHI.
Related
JPMorgan Downgrades Apollo Tyres: Navigating Commodity Headwinds and Sector Re-rating
JPMorgan Bullish on TVS Motor: Target Price Hiked to ₹4,440 as Resilience Outshines Sector Risks
JPMorgan Shifts Stance on Escorts Kubota: Upgrade to Neutral Amid Sector Recalibration
Geopolitical Friction in Hormuz: Oil Majors Flag Costs of Proposed Tolls and India’s Readiness Gaps
Recent
Waaree Energies Q4 Net Profit Surges 71% to ₹1,060 Crore as Revenue Doubles
Indegene Targets EBITDA Margin Recovery to 22% by H2 FY2027 via Strategic Biopharm Integration
Biocon Bengaluru Plant Receives 5 US FDA Procedural Observations with Zero Data Integrity Issues
SPARC Sells Priority Review Voucher for $195 Million to Fund R&D Pipeline